PTGDR and airway hyperresponsiveness: In contrast, intratracheal administration of DP1 agonist BW245c protected mice from airway hyperresponsiveness and lung eosinophilia in a OVA models of experimental asthma, thereby counteracting DP2-mediated proinflammatory responses (30, 71).